More than a year ago, I wrote about the failure of two trials of a new Alzheimer’s treatment, called aducamumab.
Subscribe to:
Post Comments (Atom)
< + > The Growing Gap Between Healthcare Risk and Healthcare Governance
The following is a guest article by Sam Peters, Chief Product Officer at IO Healthcare organizations are moving quickly to adopt artificial...
No comments:
Post a Comment